In HER2+ cancers, there is an ongoing phase I/IB clinical trial of the combination of T-DXd and an ATR inhibitor in patients with advanced solid tumors expressing the HER2 protein or gene (DASH trial, ClinicalTrials.gov identifier: NCT04704661). This evidence concerns the gene ERBB2 and cancer.